Development and evaluation of a tool to optimise inhaler selection prior to hospital discharge following an exacerbation of COPD.
Price E. et al, (2024), ERJ open research, 10, 10 - 2024
Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trial
Png ME. et al, (2024), British Journal of General Practice, BJGP.2023.0444 - BJGP.2023.0444
Early Video Assisted Thoracoscopic Surgery (VATS) or Intrapleural Enzyme Therapy (IET) in Pleural Infection - A Feasibility Randomized Controlled Trial (The Third Multicenter Intrapleural Sepsis Trial - MIST-3).
Bedawi EO. et al, (2023), American journal of respiratory and critical care medicine
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease.
Gbinigie O. et al, (2023), BMJ open, 13
The randomised thoracoscopic talc poudrage+indwelling pleural catheters versus thoracoscopic talc poudrage only in malignant pleural effusion trial (TACTIC): study protocol for a randomised controlled trial
Dipper A. et al, (2023), BMJ Open Respiratory Research, 10, e001682 - e001682
Antibiotic review kit for hospitals (ARK-Hospital): a stepped-wedge cluster-randomised controlled trial
Llewelyn MJ. et al, (2023), The Lancet Infectious Diseases, 23, 207 - 221
Antibiotic Review Kit for Hospitals (ARK-Hospital): a stepped wedge cluster randomised controlled trial
Llewelyn MJ. et al, (2022)
Role of thoracic ultrasonography in pleurodesis pathways for malignant pleural effusions (SIMPLE): an open-label, randomised controlled trial
Psallidas I. et al, (2022), The Lancet Respiratory Medicine, 10, 139 - 148
Pleural Fluid Has Pro-Growth Biological Properties Which Enable Cancer Cell Proliferation
Asciak R. et al, (2021), Frontiers in Oncology, 11
Patient-derived malignant pleural mesothelioma cell cultures: a tool to advance biomarker-driven treatments
Kanellakis NI. et al, (2020), Thorax, 75, 1004 - 1008
Prospective validation of the RAPID clinical risk prediction score in adult patients with pleural infection: the PILOT study
Corcoran JP. et al, (2020), European Respiratory Journal, 56, 2000130 - 2000130
Antibiotic Review Kit for Hospitals (ARK-Hospital): study protocol for a stepped-wedge cluster-randomised controlled trial
Walker AS. et al, (2019), Trials, 20
Cost-effectiveness of intrapleural use of tissue plasminogen activator and DNase in pleural infection: evidence from the MIST2 randomised controlled trial.
Luengo-Fernandez R. et al, (2019), The European respiratory journal, 54
Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial
Brims F. et al, (2019), Thorax, 74, 354 - 361
Randomised Ambulatory Management of Primary Pneumothorax (RAMPP): protocol of an open-label, randomised controlled trial
Hallifax R. et al, (2019), BMJ Open Respiratory Research, 6, e000403 - e000403
Biological effect of tissue plasminogen activator (t-PA) and DNase intrapleural delivery in pleural infection patients.
Kanellakis NI. et al, (2019), BMJ open respiratory research, 6
THE BIOLOGICAL EFFECT OF TISSUE PLASMINOGEN (T-PA) ACTIVATOR AND DNASE INTRAPLEURAL DELIVERY IN PLEURAL INFECTION PATIENTS
Kanellakis NI. et al, (2018), THORAX, 73, A243 - A243
The patient perspective of treatment for Malignant Pleural Effusion (MPE)- results of a pilot service-evaluation questionnaire.
Seymour J. et al, (2018), EUROPEAN RESPIRATORY JOURNAL, 52